Trametinib ‘New Standard of Care’ Option for Low-Grade Ovarian Cancer
Trametinib (Mekinist) improved progression‑free survival (PFS) and overall response rates (ORRs) among patients with low‑grade ovarian cancer.
Low‑grade serous ovarian cancer is a rare but aggressive subtype that traditionally has limited treatment options. Demonstrating a significant survival and response benefit with trametinib suggests a new, effective systemic therapy that could replace the current heterogeneous standard‑of‑care regimens, potentially improving outcomes for this patient population.
Bizonyítékszint: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Kapcsolódó jelek
- Scientists discover why cancer drugs don’t work for everyone
- Epithelial ovarian cancer: prevention, diagnosis, and treatment
- Gynecologic Cancer InterGroup Consensus Recommendations on Clinical Research in Ovarian Cancer
- Why anti‑estrogen therapy fails in ovarian cancer, and how to make it work
- Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements